Table 5.
Patient characteristics by center type (pediatric versus adult) for AYAs age 15–25 years who received a myeloablative allogeneic HCT between 2002 and 2007
| Characteristics | Pediatric Center | Adult Center | P-value |
|---|---|---|---|
| N(%) | N(%) | ||
| Number of patients | 130 | 92 | |
| Number of centers | 46 | 49 | |
| Age at HCT, years | <0.001 | ||
| 15–19 | 106 (82) | 22 (24) | |
| 20–25 | 24 (18) | 70 (76) | |
| KPS at HCT | 0.005 | ||
| ≥ 90 | 101 (78) | 61 (66) | |
| < 90 | 18 (14) | 28 (30) | |
| Disease status at HCT | 0.18 | ||
| CR1 | 46 (35) | 45 (49) | |
| CR2, CR1 duration <36 mos | 29 (35) | 36 (39) | |
| CR2, CR1 duration ≥ 36 mos | 18 (14) | 7 (8) | |
| CR2, CR1 duration unknown | 7 (5) | 4 (4) | |
| Interval from diagnosis to CR1, months | 0.003 | ||
| <1 | 54 (48) | 21 (25) | |
| 1–6 | 55 (49) | 55 (65) | |
| ≤ 6 | 4 (4) | 8 (10) | |
| Time from diagnosis to HCT, months | 0.019 | ||
| <6 | 26 (20) | 30 (33) | |
| 6–12 | 23 (18) | 22 (24) | |
| ≥ 12 | 81 (62) | 40 (43) | |
| Cytogenetic risk | 0.34 | ||
| High risk | 35 (27) | 17 (18) | |
| Normal | 33 (25) | 31 (34) | |
| Other | 35 (27) | 22 (24) | |
| Not tested/unknown | 27 (21) | 22 (24) | |
| Graft type | <0.001 | ||
| Bone Marrow | 74 (57) | 24 (26) | |
| Peripheral Blood | 56 (43) | 68 (74) | |
| HLA match | 0.11 | ||
| HLA-identical sibling | 21 (16) | 19 (21) | |
| Unrelated, well matched | 68 (52) | 49 (53) | |
| Unrelated, partially matched | 26 (20) | 22 (24) | |
| Unrelated, mismatched | 12 (9) | 1 (1) | |
| Unrelated, unknown degree of match | 3 (2) | 1 (1) | |
| Conditioning | 0.04 | ||
| TBI/Cy | 102 (78) | 63 (68) | |
| Cy/Bu | 4 (3) | 4 (4) | |
| TBI/etoposide | 15 (12) | 12 (13) | |
| TBI/other | 8 (6) | 5 (5) | |
| Other | 1 (1) | 8 (9) | |
| GVHD prophylaxis | <0.01 | ||
| CSA+ MTX +/− other | 53 (41) | 19 (21) | |
| FK506 + MTX +/− other | 35 (27) | 44 (48) | |
| T cell depletion | 21 (16) | 3 (3) | |
| Other | 21 (16) | 26 (28) |
Abbreviations: AYAs – Adolescent and young adults; KPS – Karnofsky performance status; HCT – hematopoietic cell transplantation; CR – complete remission; HLA – human leukocyte antigen; TBI – total body irradiation; Cy – cyclophosphamide; Bu – busulfan; GVHD – graft-versus-host disease; CSA – cyclosporine; MTX – methotrexate